Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-07-10
2007-07-10
Tsang, Cecilia J. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S410000, C514S019300, C548S424000, C548S429000, C548S430000
Reexamination Certificate
active
10280940
ABSTRACT:
The present invention relates to peptidomimetic compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3–NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention.
REFERENCES:
patent: WO 97/43310 (1997-11-01), None
patent: WO 98/17679 (1998-04-01), None
patent: WO 98/46630 (1998-10-01), None
patent: WO 99/07733 (1999-02-01), None
patent: WO 99/07734 (1999-02-01), None
patent: WO 99/50230 (1999-10-01), None
patent: WO 99/64442 (1999-12-01), None
patent: WO 00/09543 (2000-02-01), None
patent: WO 00/09558 (2000-02-01), None
patent: 01/74768 (2001-10-01), None
patent: 02/08244 (2002-01-01), None
LaPlante, S.R., et al., “NMR Line-Broadening and Transferred NOESY as a Medicinal Chemistry Tool for Studying Inhibitors of the Hepatits C Virus NS3 Protease Domain,”Bioorgan.&Med. Chem. Ltrs,10:2271-2274 (2000).
Llinás-Brunet, M., et al., “Highly Potent and Selective Peptide-Based Inhibitors of the Hepatitis C Virus Serine Protease: Towards Smaller Inhibitors,”Bioorgan.&Med. Chem Ltrs.,10:2267-2270 (2000).
Dunsdon, R. M., et al., “Solid Phase Synthesis of Aminoboronic Acids: Potent Inhibitors of the Hepatitis C Virus NS3 Proteinase,”Bioorg.&Med. Chem. Ltrs.,10:1577-1579 (2000).
Han, W., et al., “α-Ketoesters and α-Diketones as HCV NS3 Protease Inhibitors,”Bioorgan.&Med. Chem. Ltrs.,10:711-713 (2000).
Llinás-Brunet, M., et al., “Peptide-Based Inhibitors of the Hepatitis C Virus Serine Protease,”Bioorgan.&Med. Chem. Ltrs.,8:1713-1718 (1998).
Farmer Luc J.
Perni Robert B.
Pitlik Janos
van Drie, Jr. John H.
Audet Maury
Kelly Susan C.
Tsang Cecilia J.
Vertex Pharmaceuticals Inc.
LandOfFree
Inhibitors of serine proteases, particularly HCV NS3-NS4A... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of serine proteases, particularly HCV NS3-NS4A..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of serine proteases, particularly HCV NS3-NS4A... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3736967